Operational Status
Distribution system
DCL boasts an extensive product distribution network that covers all provinces and cities in Vietnam, establishing itself as a trusted pharmaceutical supplier for numerous large hospitals Cuu Long Pharmaceutical has further enhanced its reach by expanding to 13 branches and over 55 distributors nationwide.
Since the first quarter of 2015, DCL has operated as a subsidiary of F.I.T Group JSC, which has made significant investments in both capital and human resources to support DCL's growth The comprehensive restructuring plan has led to the recruitment of key personnel across various departments, including administration, operations, production, and sales, aimed at enhancing business activities and effectively managing the company's debt Additionally, DCL is receiving ongoing capital investments to expand and upgrade its factory, thereby increasing production capacity.
With substantial backing from its parent company, DCL aims to establish itself as the premier pharmaceutical enterprise in Vietnam, focusing on the production of innovative pharmaceuticals and medical equipment This ambition is driven by a commitment to continuous research and development of advanced product lines.
The analysis of financial statements for Cu Long Pharmaceutical Joint Stock Company highlights the company's commitment to enhancing its machinery systems and developing a skilled workforce In addition to its production and business operations, Cu Long actively engages in social responsibility initiatives, emphasizing community value sharing, environmental protection, employee welfare, and the cultivation of a positive corporate culture aligned with its core management values.
Company Position
DCL is a in 10 largest pharmaceutical manufacturing companies in Vietnam.
The company boasts a network of 678 agents and retail pharmacies across the nation, serving over 4,000 customers both domestically and internationally In addition to its robust domestic market presence, the company also exports its products to countries such as Cambodia, Laos, Myanmar, and Nigeria.
The company is currently manufacturing and supplying to the market more than 250 kinds of Pharmaceuticals.
The company currently has 5 operating factories, of which 4 meet GMP-WHO standards.
Company's Outlook
The General Statistics Office of Vietnam predicts that the country's population will reach 102.7 million by 2029, driven by average fertility rates This population growth, coupled with an aging demographic, is expected to significantly increase the demand for healthcare services and pharmaceuticals in Vietnam.
The Capsule Factory Phase 4 expansion project, completed and operational since the second quarter of 2021, has successfully installed four new capsule production lines This enhancement has increased the factory's capacity to 8.56 billion follicles per year.
The Benovas medical equipment factory project commenced construction in Q1 2021 and is anticipated to be operational by Q2 2022, boasting a designed capacity of 300 million units.
The CUU LONG Pharmaceutical Joint Stock Company specializes in the production of medical equipment, catering to both domestic and international markets Their annual output is dedicated to meeting the medical needs of various sectors, ensuring high-quality standards for their products The company's commitment to innovation and excellence positions it as a key player in the pharmaceutical industry.
Development Strategy
Building the Company to become one of the leading national pharmaceutical companies in the field of manufacturing and trading pharmaceuticals, cosmetics, functional foods and medical equipment and instruments.
In-house product portfolio enhancement.
Cooperation in product outsourcing (CMO) or brand acquisition.
Research and invest in a pharmaceutical factory that meets EU-GMP standards.
Core Values and Mission Vision
The financial statement analysis of Cuulong Pharmaceutical Joint Stock Company provides insights into its economic performance and operational efficiency This report delves into key financial metrics, highlighting trends in revenue, profitability, and liquidity By evaluating the company's financial health, stakeholders can make informed decisions regarding investments and strategic planning The analysis emphasizes the importance of understanding financial statements for assessing the company's position within the pharmaceutical industry.
Companies in the same industry
- On the stock exchange today, the number of stocks in the pharmaceutical industry also has a few notable names outside (DCL - Cuu Long Pharmaceutical JSC) such as:
DMC - Domesco Medical Import Export Joint Stock Company.
DHG - Hau Giang Pharmaceutical Joint Stock Company.
DBT - Ben Tre Pharmaceutical Joint Stock Company.
OPC - OPC Pharmaceutical Joint Stock Company.
JVC - Viet Nhat Medical Equipment Joint Stock Company.
DBD - Binh Dinh Pharmaceutical - Medical Equipment Joint Stock Company.
Equity and Shareholding Information
Price of the first trading day
The group report provides a comprehensive analysis of the financial statements of Cu Long Pharmaceutical Joint Stock Company It evaluates key financial metrics, trends, and performance indicators, offering insights into the company's financial health and operational efficiency This analysis is crucial for stakeholders to understand the company's market position and make informed decisions By examining revenue growth, profitability, and asset management, the report highlights areas of strength and potential risks, ensuring a thorough understanding of Cu Long Pharmaceutical's financial landscape.
Chairman of the Board of Directors Nguyen Van Sang
Member of the Board of Directors Nguyen Ngoc Bich
Member of the Board of Directors Nguyen Ninh Dung
Member of the Board of Directors Tuong Thi Thu Hanh
Member of the Board of Directors Bui Hong Hanh
Member of Supervisory Board Le Thi Thuong
Member of Supervisory Board Pham Thi Hue
Member of Supervisory Board Phan Thi Hoa
General Director Vu Thi Minh Hoai
Deputy General Director Nguyen Trong Duc
The analysis of financial statements for Cu Long Pharmaceutical Joint Stock Company reveals key insights into the company's performance and financial health This report examines various financial metrics, including revenue growth, profitability, and liquidity ratios, to provide a comprehensive overview By evaluating these indicators, stakeholders can better understand the company's operational efficiency and market position The findings highlight areas of strength and potential improvement, guiding future strategic decisions for sustained growth in the pharmaceutical industry.
Chief Financial Officer Nghiem Xuan Truong
Chief Accountant Nguyen Lam Minh Thuong
Information disclosure representative Nguyen Ngoc Bich Ly
The analysis of financial statements for Cuulong Pharmaceutical Joint Stock Company provides insights into the company's fiscal health and operational efficiency This report examines key financial metrics, including revenue growth, profitability, and liquidity ratios, to assess the company's performance over the reporting period By evaluating these indicators, stakeholders can better understand Cuulong Pharmaceutical's market position and strategic direction, facilitating informed decision-making for future investments.
The financial statement analysis of Cu Long Pharmaceutical Joint Stock Company reveals critical insights into its fiscal health and operational efficiency This comprehensive report evaluates key financial metrics, including revenue growth, profitability ratios, and liquidity indicators By examining these elements, stakeholders can better understand the company's performance trends and make informed decisions The analysis also highlights areas for potential improvement and strategic investment, ensuring that Cu Long Pharmaceutical remains competitive in the evolving pharmaceutical market.
This report provides a comprehensive analysis of the financial statements of Cu Long Pharmaceutical Joint Stock Company It evaluates the company's financial performance, highlighting key metrics and trends that are crucial for stakeholders The analysis focuses on revenue growth, profitability, and liquidity ratios, offering insights into the company's operational efficiency and market position Additionally, it discusses potential risks and opportunities within the pharmaceutical sector, emphasizing the importance of strategic planning for future growth.
The financial statements analysis of Cu Long Pharmaceutical Joint Stock Company reveals key insights into its fiscal health and operational efficiency This comprehensive report evaluates the company's revenue trends, profitability ratios, and overall financial performance By examining these critical metrics, stakeholders can gain a clearer understanding of the company's market position and potential for future growth The analysis also highlights areas for improvement and strategic opportunities within the pharmaceutical sector.
General analysis and financial situation
The IQVIA Institute has classed Vietnam as a Pharmerging Market Vietnam is third on the list, trailing only Argentina and Pakistan in terms of growth rate.
Vietnam is experiencing rapid population aging, with the proportion of individuals aged 65 and older expected to double from 7% to 14% in just 18 years, a significantly shorter timeframe than countries like Thailand, Japan, Australia, and France By 2039, it is projected that over 15% of Vietnam's population will be aged 65 and above, marking the beginning of a significant demographic shift between 2026 and 2039.
According to GSO, the population over 60 years old will be 21 million people,equivalent to 20% of the total population in 2038 and 27 million ~ 25% of the total population in 2050.
The financial statement analysis of Cuu Long Pharmaceutical Joint Stock Company provides critical insights into the company's performance and financial health This comprehensive report evaluates key financial metrics, trends, and ratios to assess profitability, liquidity, and solvency By examining the company's revenue growth, cost management, and investment strategies, stakeholders can make informed decisions The analysis highlights areas of strength and potential risks, ensuring a thorough understanding of the company's market position within the pharmaceutical industry.
In 2019, Vietnam experienced a significantly high death rate from non-communicable diseases, reaching 81%, which is notably higher than its regional neighbors: Singapore at 75%, Thailand at 77%, Indonesia at 76%, Malaysia at 73%, and the Philippines at 70% Alarmingly, this rate has been on the rise in recent years, highlighting a growing public health concern.
In Vietnam, individuals aged 65 and older typically suffer from an average of three diseases, while those over 80 experience an average of 6.9 health conditions Consequently, the medical examination and treatment costs for the elderly are 7 to 10 times higher than those for younger populations.
This report provides a comprehensive analysis of the financial statements of Cu Long Pharmaceutical Joint Stock Company It examines key financial metrics and trends to assess the company's performance and stability The analysis highlights significant factors influencing the company's financial health, including revenue growth, profitability, and liquidity ratios Additionally, it offers insights into the company's market position and competitive landscape within the pharmaceutical industry Overall, this report serves as a valuable resource for stakeholders seeking to understand Cu Long Pharmaceutical's financial dynamics and future prospects.
Vietnam's healthcare market was valued at $16.2 billion in 2020, representing 6.0% of the country's GDP Health spending is projected to increase to $23.3 billion by 2025 and $33.8 billion by 2030, with a compound annual growth rate (CAGR) of 7.6% from 2020 to 2030 The commitment to universal healthcare will significantly contribute to the industry's growth The government aims for 95% of the population to be enrolled in national insurance by 2025, up from 90.85% in 2020, indicating a strong likelihood of achieving this goal.
Government initiatives to enhance healthcare accessibility and affordability are key drivers of industry growth The objective is to lower out-of-pocket medical expenses for households to 35% by 2025 and 30% by 2030, down from the current rate of 43% This figure significantly exceeds the World Health Organization's recommended level of 20-30%.
The analysis of financial statements for Cu Long Pharmaceutical Joint Stock Company provides insights into the company's financial health and operational performance This report evaluates key financial metrics, including revenue trends, profitability, and liquidity ratios, to assess the company's growth potential and market position By examining these financial indicators, stakeholders can make informed decisions regarding investments and strategic planning within the pharmaceutical sector.
Pharmaceutical sales are expected to reach $7.51 billion by 2025, accounting for about 1.78% of GDP and 32.2% of the target for health care, with a CAGR (2020-
The long-term growth of the pharmaceutical industry is primarily driven by investments from multinational companies, which enhance the quality of medical examinations and treatments while also broadening the scope of social and demographic health insurance in the country.
Inventory ratios
Vòng quay hàng tồn kho
Thời gian trung bình xử lý HTK (ngày)
PMC Company demonstrates effective inventory management, maintaining a ratio greater than 1, with minimal fluctuations over the years, ranging from 0.03% to 0.21% This indicates that the company operates at a safe inventory level, with medicinal products typically having a shelf life of 3-4 years By 2021, PMC has strategically chosen to maintain a lower inventory, resulting in an inventory turnover period of 110.01 days, allowing the company to turn over its average inventory approximately 1.05 times.
Vòng quay tài sản
Bảng tỷ số vòng quay tài sản (Đơn vị giá x1000 (VND)
This report provides a comprehensive analysis of the financial statements of Cu Long Pharmaceutical Joint Stock Company It examines key financial metrics and performance indicators to assess the company's fiscal health and operational efficiency The analysis highlights trends in revenue, profitability, and expenses, offering insights into the company's financial stability and growth potential By evaluating these factors, stakeholders can make informed decisions regarding investments and strategic planning for Cu Long Pharmaceutical.
Tổng tài sản bình quân
Hệ số vòng quay tổng tài sản (lần)
Over the years, the turnover of fixed assets has shown a gradual decline, fluctuating between values greater than and less than 1 in 2021, indicating that the company has effectively utilized its assets for high efficiency Despite stable yet decreasing net sales figures, the ability to generate revenue remains notable; in 2019, for every 1 VND of assets, the company produced 1.26 VND in revenue.
Vòng quay tài sản cố định
Bảng tỷ số vòng quay tài sản cố định (Đơn vị giá x1000 (VND)
Vòng quay tài sản cố định
From 2019 to 2021, the fixed asset turnover ratio declined from 9.76 to 7.28, indicating that for every 1 dong of fixed assets, the company generated 7.28 dong in net revenue This decrease is largely attributed to the company's shift towards exploiting the OTC channel following new pharmaceutical policies that favored low-priced drugs Additionally, part of the company has not been operating at full capacity due to ongoing quality inspections and upgrades to transmission lines Overall, despite these challenges, the company's revenue has seen a slight increase over the years.
Vòng quay tài sản ngắn hạn
Bảng tỷ số vòng quay tài sản ngắn hạn (Đơn vị giá x1000 (VND)
The analysis of the financial statements for Cu Long Pharmaceutical Joint Stock Company reveals key insights into the company's fiscal health and operational performance This report focuses on the company's revenue trends, expense management, and overall profitability, providing a comprehensive overview of its financial stability By examining the balance sheet, income statement, and cash flow statement, we can identify critical areas for growth and potential risks The findings aim to assist stakeholders in making informed decisions regarding investments and strategic planning within the pharmaceutical sector.
Vòng quay tài sản ngắn hạn
PMC has experienced a gradual decline in the efficiency of utilizing short-term assets over the years, particularly from 2019 to 2021 Despite an increase in short-term assets, the company's short-term asset turnover remains high, exceeding 1, indicating effective revenue generation This suggests that PMC's management is successfully transitioning from short-term to long-term assets while maintaining strong short-term asset turnover.
Chart Title vòng quay tài s n cốố đ nh ả ị vòng quay tài s n ngắốn h n ả ạ vòng quay t ng tài s n ổ ả
Vòng quay Tài sản cố định
Vòng quay tài sản ngắn hạn
The financial statement analysis of Cu Long Pharmaceutical Joint Stock Company provides valuable insights into the company's performance and financial health This report examines key financial metrics and trends, highlighting areas of growth and potential risks By evaluating revenue streams, expenses, and profitability ratios, stakeholders can make informed decisions regarding investments and strategic planning Understanding these financial statements is crucial for assessing the company's position in the competitive pharmaceutical industry.
Phân tích tỷ suất sinh lời
Net income is a key metric for investors assessing a company's profitability, while margins offer valuable insights into management performance Margins represent income as a percentage of sales, enabling comparisons of profitability across different companies The three primary types of margins include gross margin, operating margin, and net profit margin.
3.6.1.1 Tỷ suất lợi nhuận gộp
Bảng tỷ suất lợi nhuận gộp (ĐVT: Triệu đồng)
In 2019, the company achieved its highest gross profit margin at 38.32%, indicating that every 100 VND of revenue generated 38.32 VND in profit However, this margin slightly decreased to 38.30% in 2020 and further declined to 35.60% in 2021 The primary reason for this reduction was a decrease in both net revenue and gross profit.
Tỷ suất lợi nhuận sau thuế trên doanh thu (ROS)
Tỷ suất lợi nhuận sau thuế trên doanh thu
This report provides a comprehensive analysis of the financial statements of Cuu Long Pharmaceutical Joint Stock Company It evaluates key financial metrics and performance indicators to assess the company's financial health and operational efficiency The analysis aims to identify trends, strengths, and areas for improvement within the organization, offering valuable insights for stakeholders and potential investors.
In 2020, the company achieved remarkable profit margins, with a return on sales (ROS) index of 16.19%, indicating that for every 100 VND in revenue, 16.19 VND is profit An analysis of the ROS index over the past three years (2019-2021) shows a stable performance, with ratings of 16.01% to 15.63%, reflecting the company's sustainable and profitable business model PMC is actively striving to compete with industry peers and consistently improve its performance, solidifying its position as a strong player in the pharmaceutical and medical sectors.
Tỷ suất sinh lời trên tài sản bình quân (ROA)
Tỷ suất sinh lời trên tài sản bình quân (ROA)
Tổng Tài Sản Bình Quân
Between 2019 and 2021, the company's Return on Assets (ROA) exhibited a declining trend, indicating that by 2021, the firm generated a profit of 14.71 dong for every 100 dong of assets ROA serves as a crucial metric for evaluating investment profitability, reflecting the company's performance independent of its financial structure Specifically, the ROA decreased from 18.35% in 2020 to 14.71% in 2021, marking a year-on-year decline of 1.8% and a substantial drop of 13.64% over the two-year period.
Tỷ suất sinh lời trên vốn chủ sở hữu bình quân (ROE)
Tỷ suất sinh lời trên vốn chủ sở hữu bình quân (ROE)
The analysis of the financial statements for Cuulong Pharmaceutical Joint Stock Company provides critical insights into its fiscal health and operational performance This report evaluates key financial metrics, including revenue growth, profitability ratios, and liquidity indicators, to assess the company's overall financial stability By examining trends over multiple reporting periods, stakeholders can identify strengths and weaknesses within the organization The findings highlight areas for potential improvement and strategic investment, ensuring that Cuulong Pharmaceutical remains competitive in the pharmaceutical industry.
Vốn chủ sở hữu bình quân
From 2019 to 2021, ROE plummets to 2021 from 23.54% to 21.43% and continue to decrease to 17.2% in 2021 This shows 100 equity of the company ability.energy generated 17.2 dong of profit.
Hệ số giá trên thu nhập (P/E)
Hệ số giá trên thu nhập (P/E)
P / E measures the relationship between the market price and the earnings for each security
The P/E also shows how many times the current stock price is higher than its income, or how much an investor must pay for a penny of income
The company's P/E ratio increased partially year over year from 6,625 to 9,364 shows dividend growth.
VietnamCredit (2021) Overview of vietnam’s pharmaceutical industry Báo cáo tài chính hợp nhất đã kiểm toán 2018 của DCL
The financial statements of Cuu Long Pharmaceutical Joint Stock Company have been thoroughly analyzed in this group report This analysis provides insights into the company's financial performance, highlighting key metrics and trends It aims to assess the company's profitability, liquidity, and overall financial health, which are crucial for stakeholders making informed decisions The report also discusses potential risks and opportunities within the pharmaceutical sector, emphasizing the importance of strategic planning and management in achieving sustainable growth.